SG11201601733VA - Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease - Google Patents
Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel diseaseInfo
- Publication number
- SG11201601733VA SG11201601733VA SG11201601733VA SG11201601733VA SG11201601733VA SG 11201601733V A SG11201601733V A SG 11201601733VA SG 11201601733V A SG11201601733V A SG 11201601733VA SG 11201601733V A SG11201601733V A SG 11201601733VA SG 11201601733V A SG11201601733V A SG 11201601733VA
- Authority
- SG
- Singapore
- Prior art keywords
- diagnosis
- treatment
- inflammatory bowel
- bowel disease
- bowel syndrome
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Ecology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361888658P | 2013-10-09 | 2013-10-09 | |
| PCT/US2014/059957 WO2015054529A1 (en) | 2013-10-09 | 2014-10-09 | Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201601733VA true SG11201601733VA (en) | 2016-04-28 |
Family
ID=52813648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201601733VA SG11201601733VA (en) | 2013-10-09 | 2014-10-09 | Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9851361B2 (enExample) |
| EP (1) | EP3054977B1 (enExample) |
| JP (1) | JP6567509B2 (enExample) |
| KR (1) | KR102259588B1 (enExample) |
| CN (1) | CN105744956B (enExample) |
| AU (2) | AU2014331841B2 (enExample) |
| BR (1) | BR112016007474A2 (enExample) |
| CA (1) | CA2923651C (enExample) |
| CL (1) | CL2016000820A1 (enExample) |
| ES (1) | ES2892905T3 (enExample) |
| IL (1) | IL244971B2 (enExample) |
| MX (1) | MX383423B (enExample) |
| NZ (1) | NZ717633A (enExample) |
| PE (1) | PE20160882A1 (enExample) |
| PL (1) | PL3054977T3 (enExample) |
| PT (1) | PT3054977T (enExample) |
| RU (1) | RU2683781C2 (enExample) |
| SG (1) | SG11201601733VA (enExample) |
| WO (1) | WO2015054529A1 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9851361B2 (en) | 2013-10-09 | 2017-12-26 | Cedars-Sinai Medical Center | Methods of comparing anti-vinculin and anti-cytolethal distending toxin antibodies as they relate to irritable bowel syndrome |
| US9869676B2 (en) | 2009-02-11 | 2018-01-16 | Cedars-Sinai Medical Center | Antibody to cytolethal distending toxin of Campylobacter jejuni |
| US9952223B2 (en) | 2012-09-17 | 2018-04-24 | Cedars-Sinai Medical Center | Method for detecting anti-vinculin antibodies in a subject with an IBS symptom |
| US10132814B2 (en) | 2014-10-09 | 2018-11-20 | Cedars-Sinai Medical Center | Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11693009B2 (en) | 2009-02-11 | 2023-07-04 | Cedars-Sinai Medical Center | Methods for detecting post-infectious irritable bowel syndrome |
| CN105784989A (zh) * | 2016-05-17 | 2016-07-20 | 上海凯璟生物科技有限公司 | 一种肠易激综合症标志物CdtB抗体检测试剂盒及其制备方法 |
| CN106053827A (zh) * | 2016-05-17 | 2016-10-26 | 上海凯璟生物科技有限公司 | 一种肠易激综合症标志物Vinculin抗体检测试剂盒及其制备方法 |
| KR102481305B1 (ko) | 2016-05-20 | 2022-12-26 | 세다르스-신나이 메디칼 센터 | 유전자에 기반한 염증성 장 질환의 진단 |
| JP2020507755A (ja) | 2017-01-30 | 2020-03-12 | シーダーズ−サイナイ メディカル センター | 強皮症の診断法 |
| RU2763258C1 (ru) * | 2020-07-13 | 2021-12-28 | Евгения Николаевна Воронина | Способ дифференциальной диагностики воспалительных заболеваний кишечника у детей по комплексу клинико-анамнестических, лабораторных и инструментальных критериев |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691151A (en) * | 1994-10-07 | 1997-11-25 | Regents Of University Of California | Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca |
| US6562629B1 (en) | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| FR2806805A1 (fr) | 2000-03-22 | 2001-09-28 | Centre Nat Rech Scient | SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS |
| US20040018528A1 (en) * | 2002-05-17 | 2004-01-29 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
| JP2006515165A (ja) | 2002-09-16 | 2006-05-25 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための新規組成物と方法 |
| US7595386B2 (en) | 2003-01-24 | 2009-09-29 | William Beaumont Hospital | Methods and compositions for heat activated gene therapy using cytolethal distending toxin |
| EP1617846A1 (en) * | 2003-04-08 | 2006-01-25 | Progenics Pharmaceuticals, Inc. | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
| DE602004030586D1 (de) * | 2003-09-15 | 2011-01-27 | Oklahoma Med Res Found | Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis |
| CN102634524B (zh) | 2003-12-05 | 2014-03-05 | 扶桑药品工业株式会社 | 细胞致死肿胀毒素及以其为目标的弯曲杆菌属细菌的检测 |
| EP2102367A2 (en) | 2006-11-09 | 2009-09-23 | XDX, Inc. | Methods for diagnosing and monitoring the status of systemic lupus erythematosus |
| EP2562544A1 (en) | 2007-12-20 | 2013-02-27 | InDex Diagnostics AB | kits for use in the differentiation of IBD and IBS and further distinction between disease types of IBD |
| ES2529060T3 (es) | 2008-11-24 | 2015-02-16 | Cedars-Sinai Medical Center | Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos |
| AU2010213773B2 (en) | 2009-02-11 | 2014-07-17 | Cedars-Sinai Medical Center | Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome |
| EP2396652B1 (en) | 2009-02-11 | 2017-12-13 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel syndrome based on cytolethal distending toxin |
| FR2942541A1 (fr) | 2009-02-25 | 2010-08-27 | Assist Publ Hopitaux De Paris | Procede de diagnostic d'une vascularite |
| RU2397178C1 (ru) * | 2009-02-27 | 2010-08-20 | Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса |
| IT1400989B1 (it) | 2010-07-13 | 2013-07-05 | Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L | Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale. |
| GB201017520D0 (en) | 2010-10-15 | 2010-12-01 | Sense Proteomic Ltd | Biomarkers |
| CA2884413C (en) | 2012-09-17 | 2022-11-01 | Cedars-Sinai Medical Center | Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia |
| AU2014331841B2 (en) | 2013-10-09 | 2020-03-12 | Cedars-Sinai Medical Center | Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease |
| SG11201702395WA (en) | 2014-10-09 | 2017-04-27 | Cedars Sinai Medical Center | Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease |
| CN106091069A (zh) | 2016-06-15 | 2016-11-09 | 安徽省绿巨人环境技术有限公司 | 一种废水再利用装置 |
| JP2020507755A (ja) | 2017-01-30 | 2020-03-12 | シーダーズ−サイナイ メディカル センター | 強皮症の診断法 |
-
2014
- 2014-10-09 AU AU2014331841A patent/AU2014331841B2/en active Active
- 2014-10-09 SG SG11201601733VA patent/SG11201601733VA/en unknown
- 2014-10-09 WO PCT/US2014/059957 patent/WO2015054529A1/en not_active Ceased
- 2014-10-09 KR KR1020167011774A patent/KR102259588B1/ko active Active
- 2014-10-09 EP EP14851688.3A patent/EP3054977B1/en active Active
- 2014-10-09 CN CN201480055994.5A patent/CN105744956B/zh active Active
- 2014-10-09 NZ NZ717633A patent/NZ717633A/en unknown
- 2014-10-09 JP JP2016521777A patent/JP6567509B2/ja active Active
- 2014-10-09 PE PE2016000430A patent/PE20160882A1/es unknown
- 2014-10-09 PT PT14851688T patent/PT3054977T/pt unknown
- 2014-10-09 RU RU2016116766A patent/RU2683781C2/ru active
- 2014-10-09 CA CA2923651A patent/CA2923651C/en active Active
- 2014-10-09 PL PL14851688T patent/PL3054977T3/pl unknown
- 2014-10-09 MX MX2016004167A patent/MX383423B/es unknown
- 2014-10-09 ES ES14851688T patent/ES2892905T3/es active Active
- 2014-10-09 IL IL244971A patent/IL244971B2/en unknown
- 2014-10-09 BR BR112016007474A patent/BR112016007474A2/pt not_active Application Discontinuation
- 2014-10-09 US US15/021,850 patent/US9851361B2/en active Active
-
2016
- 2016-04-08 CL CL2016000820A patent/CL2016000820A1/es unknown
-
2017
- 2017-12-12 US US15/839,366 patent/US10352944B2/en active Active
-
2020
- 2020-05-27 AU AU2020203468A patent/AU2020203468A1/en not_active Abandoned
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9869676B2 (en) | 2009-02-11 | 2018-01-16 | Cedars-Sinai Medical Center | Antibody to cytolethal distending toxin of Campylobacter jejuni |
| US10527621B2 (en) | 2009-02-11 | 2020-01-07 | Cedars-Sinai Medical Center | Antibody to cytolethal distending toxin of Campylobacter jejuni |
| US9952223B2 (en) | 2012-09-17 | 2018-04-24 | Cedars-Sinai Medical Center | Method for detecting anti-vinculin antibodies in a subject with an IBS symptom |
| US10466254B2 (en) | 2012-09-17 | 2019-11-05 | Cedars-Sinai Medical Center | Method of measuring a level of anti-vinculin antibodies in a biological sample |
| US9851361B2 (en) | 2013-10-09 | 2017-12-26 | Cedars-Sinai Medical Center | Methods of comparing anti-vinculin and anti-cytolethal distending toxin antibodies as they relate to irritable bowel syndrome |
| US10352944B2 (en) | 2013-10-09 | 2019-07-16 | Cedars-Sinai Medical Center | Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease |
| US10132814B2 (en) | 2014-10-09 | 2018-11-20 | Cedars-Sinai Medical Center | Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease |
| US10690679B2 (en) | 2014-10-09 | 2020-06-23 | Cedars-Sinai Medical Center | Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201601733VA (en) | Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease | |
| EP2968397A4 (en) | DIAGNOSIS AND TREATMENT OF FIBROSIS | |
| IL244089A0 (en) | Diagnostic methods and preparations for the treatment of glioblastoma | |
| HUE049569T2 (hu) | Immunrendszerrel kapcsolatos és gyulladásos megbetegedések kezelése | |
| EP2958936A4 (en) | METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE | |
| EP2971127A4 (en) | METHOD FOR DIAGNOSIS AND TREATMENT OF INFLAMMABLE ENDURANCE | |
| EP2968208A4 (en) | TREATMENT OF CATAPLEXIA | |
| IL275368B (en) | Diagnosis and treatment of autoimmune diseases | |
| EP2997162A4 (en) | Methods for diagnosing and treating inflammatory bowel disease | |
| PT3626270T (pt) | Tratamento de doenças cardiovasculares | |
| ZA201408059B (en) | Compositions and methods for the treatment of inflammatory bowel disease | |
| ZA201507718B (en) | The local treatment of inflammatory ophthalmic diseases | |
| EP3046629A4 (en) | Treatment of inflammatory skin disease | |
| LT3021873T (lt) | Kompozicija, skirta uždegiminių sąnarių ligų gydymui | |
| IL242516B (en) | Treatment of pulmonary and other conditions | |
| HUE042691T2 (hu) | Tiazolo-pirimidinon felhasználása gyulladásos bélbetegségek kezeléséhez | |
| EP3016968A4 (en) | Diagnosis and treatment of autoimmune diseases | |
| EP2994486A4 (en) | USE OF ANTI-EOTAXINE ANTIBODIES FOR THE TREATMENT OF CHRONICALLY INFLAMMABLE ENDURANCE | |
| PL2870968T3 (pl) | Leczenie klinoptilolitem zapalnych chorób jelit | |
| GB201318088D0 (en) | Oligonucleotide probe set and methods for the diagnosis of irritable bowel syndrome and inflammatory bowel disease | |
| SG11201506509TA (en) | Use of pidotimod to treat inflammatory bowel disease | |
| GB201320014D0 (en) | Treatment of cardiovascular disease | |
| IL241785A0 (en) | Using fidotimide to treat irritable bowel syndrome | |
| GB201521918D0 (en) | Antibodies for treatment and diagnosis of inflammatory bowel disease | |
| GB201321628D0 (en) | Treatment of disease |